Simcere Pharma Grants License for SIM0613 to Ipsen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Licensing Agreement: Simcere Pharmaceutical Group's subsidiary has signed an exclusive licensing agreement with Ipsen S.A. for the antibody-drug conjugate SIM0613, targeting LRRC15.
Financial Terms: The deal could yield up to $1.06 billion for Simcere, including a $45 million upfront payment and additional milestone payments based on development and sales.
Global Rights: Ipsen has obtained exclusive global rights outside Greater China to develop, manufacture, and commercialize SIM0613.
Market Impact: Following the announcement, Simcere's stock price decreased by 2.29% to HKD 12.810 on the Hong Kong Stock Exchange.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
